TP5 can promote the antitumor effect of oxaliplatin by inhibiting colon cancer stem cells, suggesting that TP5 may become a novel drug to target cancer stem cells, thus reducing cancer recurrence rate and improving tumor treatment efficacy, and may provide a new treatment option for patients with drug-refractory colorectal cancer. The gene discussed is TMPO; the disease is colonic neoplasm.